E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Nicholas J. Short,Hagop M. Kantarjian,Farhad Ravandi,Xuelin Huang,Nitin Jain,Naval Daver,Deborah A. Thomas,Naveen Pemmaraju,Rita Khouri,Joseph D. Khoury,Jeffrey L. Jorgensen,Yesid Alvarado,Koji Sasaki,Marina Konopleva,Guillermo Garcia-Manero,Tapan M. Kadia,Jorge E. Cortes,Christopher B. Benton,Gautam Borthakur,Jan A. Burger,Maro Ohanian,William G. Wierda,Zeev Estrov,Steven M. Kornblau,Courtney D. DiNardo,Alessandra Ferrajoli,Jovitta Jacob,Ameena Manzoor,Rebecca Garris,Susan O'Brien,Elias Jabbour +30 more
TL;DR: The addition of INO to low-intensity chemotherapy might improve outcomes in older pts with newly diagnosed ALL, and MRD negativity by 6-color flow cytometry was achieved in 36/46 pts after 1 cycle and 49/51 pts overall.
Journal ArticleDOI
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Hady Ghanem,A. Megan Cornelison,Guillermo Garcia-Manero,Hagop M. Kantarjian,Farhad Ravandi,Tapan M. Kadia,Jorge E. Cortes,Susan O'Brien,Mark Brandt,Gautam Borthakur,Elias Jabbour +10 more
TL;DR: DD/DR may be safely accomplished once the patient has achieved best objective response (preferably complete remission [CR] without impacting outcome, and Prospective evaluation of a loading dose for induction of abest objective response followed by a maintenance schedule is to be considered.
Journal ArticleDOI
Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab
Deborah A. Thomas,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,William G. Wierda,Guillermo Garcia-Manero,Elias Jabbour,Alessandra Ferrajoli,Srdan Verstovsek,Jan A. Burger,Rebecca Garris,Jorge E. Romaguera,Fredrick B. Hagemeister,Hagop M. Kantarjian +13 more
TL;DR: The outcomes for Burkitt-type lymphoma/leukemia have improved significantly with the use of short, intensive, multi-agent chemotherapy regimens.
Journal ArticleDOI
Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
Sai Prasad Desikan,Marina Konopleva,Koichi Takahashi,Curtis Lachowiez,Sanam Loghavi,Lianchun Xiao,Tapan M. Kadia,Naval Daver,Nicholas J. Short,Koji Sasaki,Gautam Borthakur,Ghayas C Issa,Abhishek Maiti,Kelly S. Chien,Yesid Alvarado,Guillermo Montalban-Bravo,Lucia Masarova,Musa Yilmaz,Michael Andreeff,Elias Jabbour,Guillermo Garcia-Manero,Steven M. Kornblau,Farhad Ravandi,Hagop M. Kantarjian,Courtney D. DiNardo +24 more
TL;DR: Venetoclax with FLAG-IDA demonstrated favorable response rates in the frontline and relapsed or refractory (R/R) setting, with overall response rate (ORR) of 97% and 70% in the Phase IIA (frontline) and Phase IIB (R)/R) respectively as discussed by the authors .
Journal ArticleDOI
Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease
Iman Aboudalle,Hagop M. Kantarjian,Nicholas J. Short,Maria Khouri,Koichi Takahashi,Maro Ohanian,Gautam Borthakur,Marina Konopleva,Naval Daver,Zeev Estrov,Yesid Alvarado,Nitin Jain,Farhad Ravandi,Guillermo Garcia-Manero,Michelle Velasquez,Patrice Nasnas,Susan O'Brien,Susan O'Brien,Elias Jabbour +18 more
TL;DR: Binatumomab, a CD19/CD3 bispecific T-cell engager antibody construct, is capable of eradicating MRD in precursor B-ALL, and possibly prolong survival, according to this open-label, single-arm, phase II trial.